Skip to content
Preprint · CC-BY via OpenAlex

High-content screening identifies FDA-approved activators of mitophagy

Carlo Fiore Viscomi, Giacomo Giacchin, Valeria Balmaceda, Marta Giacomello, Andrea Eastes, Samantha Corrà, Lucía Fernández-del-Río, Nikole Scillitani, Davide Steffan, Marco Sandri, Erika Fernández‐Vizarra, Orian S. Shirihai, Cristiane Benincá

bioRxiv (Cold Spring Harbor Laboratory) · 2026

Abstract

Mitochondrial diseases are highly heterogeneous disorders caused by defects in oxidative phosphorylation, for which only limited therapeutic options are available. The elimination of dysfunctional mitochondria via mitophagy activation is an attractive strategy to treat several mitochondrial diseases, irrespective of the underlying genetic defect. To identify pharmacological activators of this pathway, we performed a high-content screening of 1,971 FDA-approved compounds using cellular reporters of TFEB nuclear translocation and mitophagy. This screening identified 294 compounds that promoted TFEB translocation, nine of which increased the number of mitolysosomes without compromising cell viability or damaging mitochondria. Among the selected compounds, Meptazinol and Ponatinib emerged as the top-ranked mitophagy inducers in fibroblasts from patients with complex I and IV deficiency, respectively, and were prioritised for further characterisation. However, they did not rescue the bioenergetic defect, suggesting that the stimulation of mitophagy per se is not sufficient to ameliorate the OXPHOS defect in mitochondrial diseases. Overall, our findings establish a scalable platform for the identification of pharmacological activators of TFEB and identify candidate compounds for therapeutic modulation of mitophagy.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.64898/2026.11.06.764995
Canonical
link ↗
Fetched
2026-11-13 MST

Cite this

APA
Viscomi, C.F., Giacchin, G., Balmaceda, V., Giacomello, M., Eastes, A., Corrà, S., Fernández-del-Río, L., Scillitani, N., Steffan, D., Sandri, M., Fernández‐Vizarra, E., Shirihai, O.S., &amp; Benincá, C. (2026). High-content screening identifies FDA-approved activators of mitophagy. <em>bioRxiv (Cold Spring Harbor Laboratory)</em>. https://doi.org/10.64898/2026.11.06.764995
Vancouver
Viscomi CF, Giacchin G, Balmaceda V, Giacomello M, Eastes A, Corrà S, et al. High-content screening identifies FDA-approved activators of mitophagy. bioRxiv (Cold Spring Harbor Laboratory). 2026. doi:10.64898/2026.11.06.764995.
BibTeX
@unpublished{carlo2026Highco, title = {High-content screening identifies FDA-approved activators of mitophagy}, author = {Carlo Fiore Viscomi and Giacomo Giacchin and Valeria Balmaceda and Marta Giacomello and Andrea Eastes and Samantha Corrà and Lucía Fernández-del-Río and Nikole Scillitani and Davide Steffan and Marco Sandri and Erika Fernández‐Vizarra and Orian S. Shirihai and Cristiane Benincá}, journal = {bioRxiv (Cold Spring Harbor Laboratory)}, year = {2026}, doi = {10.64898/2026.11.06.764995}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings